Superiority of low‐dose benzbromarone to low‐dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion
Fei Yan,Xiaomei Xue,Jie Lu,Nicola Dalbeth,Han Qi,Qing Yu,Can Wang,Mingshu Sun,Lingling Cui,Zhen Liu,Yuwei He,Xuan Yuan,Ying Chen,Xiaoyu Cheng,Lidan Ma,Hailong Li,Aichang Ji,Shuhui Hu,Zijing Ran,Robert Terkeltaub,Changgui Li
DOI: https://doi.org/10.1002/art.42266
2022-07-19
Abstract:Objective The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion, yet the standard urate‐lowering therapy (ULT) recommendation is first line xanthine oxidase inhibition (XOI) irrespective of the cause of hyperuricemia. Here, we conducted a comparative effectiveness clinical trial of first line un‐titrated, low‐dose benzbromarone uricosuric therapy vs. XOI ULT with low‐dose febuxostat in gout with renal uric acid underexcretion. Methods A prospective, randomized, single‐center, open‐labeled trial of men with gout and renal uric acid underexcretion (defined as fractional excretion of urate <5.5% and uric acid excretion ≤600 mg/day/1.73m2) was conducted. We randomly assigned 196 participants to low‐dose benzbromarone 25 mg daily (LDBen) or low‐dose febuxostat 20 mg daily (LDFeb) for 12 weeks. All participants received daily urine alkalization with oral sodium bicarbonate. The primary endpoint was rate of achieving serum urate (SU) target <6 mg/dL. Results More participants in the LDBen group achieved the serum urate target than LDFeb (61% vs. 32%, P<0.001). Adverse events, including gout flares and urolithiasis, did not differ between groups, with the exception of more transaminase elevation in the LDFeb group (LDBen 4% vs. LDFeb 15%, P=0.008). Conclusion Compared to LDFeb, LDBen had superior urate‐lowering and similar safety in the relatively young and healthy patients with gout of renal uric acid underexcretion type.
rheumatology